Steven Seaman YOU? Author Swipe

Last 10y

ANTXR1 blockade enhances cardiac function in preclinical models of heart failure Open

Nicola Boccella, Guojun Yu, Steven Seaman, Yang Feng, Jaewon Lee , et al. · 2025

m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models Open

Mikaela D Kunika, Aarthi Kannan, Graham J. Velasco, Feng Yang, Steven Seaman , et al. · 2025

Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine carcinoma, and immune checkpoint inhibitors (ICIs) are the only approved therapy; nonetheless, resistance is notable and there is a critical need for novel effective thera…

Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform Open

Liping Yang, Timothy P. Sheets, Yang Feng, Guojun Yu, Pradip Bajgain , et al. · 2024

The majority of clinically approved drugs target proteins that are secreted or cell surface bound. However, further advances in this area have been hindered by the challenging nature of receptor deorphanization, as there are still many sec…

Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability Open

Yan Feng, Jaewon Lee, Liping Yang, Mary Beth Hilton, Karen Morris , et al. · 2023

CD276/B7-H3 represents a promising target for cancer therapy based on widespread overexpression in both cancer cells and tumor-associated stroma. In previous preclinical studies, CD276 antibody-drug conjugates (ADCs) exploiting a talirine-…

Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

L2 CAR T cells provide a survival advantage and disrupt vessels and tumor architecture in TNBC xenografts .

Figure S3 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

L2 2G and L2 3G CAR T cell normalization and functional testing.

Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

No overt toxicity detected in mice receiving TEM8 CAR T cells.

Data from The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models Open

Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher , et al. · 2023

Purpose:Patients with relapsed pediatric solid malignancies have few therapeutic options, and many of these patients die of their disease. B7-H3 is an immune checkpoint protein encoded by the CD276 gene that is overexpressed in many…

Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

No overt toxicity detected in mice receiving TEM8 CAR T cells.

Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumo…

Supplementary Methods and Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

Information about methods and data that further support the claims made in this article. This includes, but is not limited to TEM8 distribution in normal tissues, CAR T cell normalization, additional control groups and CAR toxicity studies.

Figure S3 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

L2 2G and L2 3G CAR T cell normalization and functional testing.

Figure S6 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

Mice that received systemic administration of L2 CAR T cells have normal pathology.

Supplementary Data from The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models Open

Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher , et al. · 2023

Supplemental Tables 1-2 and Supplemental Figures 1-10

Supplementary Methods and Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

Information about methods and data that further support the claims made in this article. This includes, but is not limited to TEM8 distribution in normal tissues, CAR T cell normalization, additional control groups and CAR toxicity studies.

Data from The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models Open

Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher , et al. · 2023

Purpose:Patients with relapsed pediatric solid malignancies have few therapeutic options, and many of these patients die of their disease. B7-H3 is an immune checkpoint protein encoded by the CD276 gene that is overexpressed in many…

Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

L2 CAR T cells reduce mammosphere formation when compared to irrelevant CAR control cells.

Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

L2 CAR T cells provide a survival advantage and disrupt vessels and tumor architecture in TNBC xenografts .

Figure S6 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

Mice that received systemic administration of L2 CAR T cells have normal pathology.

Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

TEM8 distribution in normal tissues

Supplementary Data from The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models Open

Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher , et al. · 2023

Supplemental Tables 1-2 and Supplemental Figures 1-10

Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

TEM8 distribution in normal tissues

Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumo…

Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer Open

Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha , et al. · 2023

L2 CAR T cells reduce mammosphere formation when compared to irrelevant CAR control cells.

Supplementary Materials and Methods, Tables 1-3, Figures 1-5 from Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma Open

Mike Cullen, Steven Seaman, Amit Chaudhary, Mi Yang, Mary Beth Hilton , et al. · 2023

Supplementary Materials and Methods, Tables 1-3, Figures 1-5 from Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma

Supplementary Materials and Methods, Tables 1-3, Figures 1-5 from Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma Open

Mike Cullen, Steven Seaman, Amit Chaudhary, Mi Yang, Mary Beth Hilton , et al. · 2023

Supplementary Materials and Methods, Tables 1-3, Figures 1-5 from Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma

Data from Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma Open

Mike Cullen, Steven Seaman, Amit Chaudhary, Mi Yang, Mary Beth Hilton , et al. · 2023

Tumor endothelial marker 8 (TEM8) was initially identified as a gene overexpressed in the vasculature of human tumors and was subsequently identified as an anthrax toxin receptor. To assess the functional role of TEM8, we dis…

Data from Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma Open

Mike Cullen, Steven Seaman, Amit Chaudhary, Mi Yang, Mary Beth Hilton , et al. · 2023

Tumor endothelial marker 8 (TEM8) was initially identified as a gene overexpressed in the vasculature of human tumors and was subsequently identified as an anthrax toxin receptor. To assess the functional role of TEM8, we dis…

Cancer cell survival depends on collagen uptake into tumor-associated stroma Open

Kuo-Sheng Hsu, James M. Dunleavey, Christopher Szot, Liping Yang, Mary Beth Hilton , et al. · 2022

Cancer cell survival depends on collagen uptake into tumor-associated stroma Open

Kuo-Sheng Hsu, James M. Dunleavey, Christopher Szot, Liping Yang, Mary Beth Hilton , et al. · 2022

Collagen I, the most abundant protein in humans, is ubiquitous in solid tumors where it provides a rich source of exploitable metabolic fuel for cancer cells. While tumor cells were unable to exploit collagen directly, here we show they ca…

Fetching topic information...